Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24017110 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10SLC7A5LAP3 | |
| Hydrochloric Acid SCHEMBL22498200 | 0.95 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10SLC7A5LAP3 | |
| Hydrochloric Acid SCHEMBL22498201 | 0.95 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10SLC7A5LAP3 | |
| SCHEMBL43238 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL6268152 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL7070779 | 0.84 | — | — | |
| Lithium Ion SCHEMBL1743232 | 0.84 | — | — | |
| SCHEMBL10625984 | 0.83 | — | — | |
| SCHEMBL19217938 | 0.80 | — | — | |
| SCHEMBL17996828 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964122-A | Polyurea copolymers | 巴斯夫欧洲公司 | 2023-10-27 | — | — | CN | claimed |
| EP-4077438-A1 | POLYUREA COPOLYMER | BASF SE (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-114846043-A | Polyurea copolymers | 巴斯夫欧洲公司 | 2022-08-02 | — | — | CN | claimed |
| CN-119894954-A | System and method for enclosing a PFAS | 巴斯夫欧洲公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024064691-A1 | SYSTEM AND METHOD FOR PFAS CONTAINMENT | BASF SE (DE) | 2024-03-28 | — | — | WO | disclosed |
| CN-116964122-A | Polyurea copolymers | 巴斯夫欧洲公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116607132-A | Plating bath composition for electroless gold plating and method of depositing gold layer | 埃托特克德国有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4077438-A1 | POLYUREA COPOLYMER | BASF SE (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114846043-A | Polyurea copolymers | 巴斯夫欧洲公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021223156-A1 | DIBORON GLYCOL ESTER, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-11-11 | — | — | WO | disclosed |
| CN-101472931-B | Organometallic compounds | PRAXAIR TECHNOLOGY INC | 2014-09-10 | — | — | CN | disclosed |
| US-7179829-B2 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| EP-1461034-B1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20050004198-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1461034-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | Aventis Pharma Deutschland GmbH (DE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2003053434-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | WO | disclosed |
| US-4739087-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739087-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | CHRM1, ARG2, ACHE | ALDH1A1 746/4885TSHR 993/4885HSD17B10 2731/4885 |
| US-20050004198-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | ACHE, CHRM1, CHRM3 | ALDH1A1 1411/4885TSHR 790/4885HSD17B10 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.